Exchange traded investment fund FinEx Cash Equivalents UCITS ETF (RUB)



RUB share class BLOOMBERG: SOLTBILL index

RUB share class
(ISIN: IE00BL3DYX33)

Index Information

Index Ticker (Bloomberg) SOLTBILL index Index Currency USD Duration 0.086 Index Ticker (Reuters) .SOLTBILL Index Provider Solactive AG

Investment Objective

The investment objective of the share class is to deliver the return of the reference index (the Solactive 1-3 month US T-Bill index) plus the return of a short USO long RUB currency overlay, minus the fees and costs of the fund. The reference index is a money market index comprised of US treasury bills. The reference index is denominated in USO

Key Information

Product Name	FinEx Cash Equivalents UCITS ETF (RUB)	
ISIN	IE00BL3DYX33	
lssuer	FinEx Funds ICAV	
Inception Date	05/07/2014	
Fund Domicile	Ireland	
UCITS V Compliant	Yes	
Fund Manager	KBA Consulting Management Limited (Great Britain)	
Base Currency	RUB	
Total Expence Ratio	0.49%	
Reference Index	Solactive 1-3 month US T-Bill Index	
Custodian/Administrator	Citi Depositary Services (Ireland)/Citibank Europe	
EUSD Taxation	Out Of Scope	
Replication Method	Full replication	
Reporting Frequency	Semi-Annually	
Close of Fiscal Year	30-September	
Fund Auditor	Grant Thornton	
Trading Taxes	No UK Stamp duty or SDRT	
Currency Hedging	No	
Minimum Purchase	1 share	
NAV per share DD 12/02/2024	3526.17 RUB	
Shares is Issue	1,736,000	
Total Fund Assets	5,228,338,788.54 RUB	

Share class return for (RUB, %)^{*}:




*The yield is indicated in the fund's currency (ruble)


Contacts

KBA Consulting Management Limited 35 Shelbourne Road Ballsbridge Dublin Ireland, D04 A4E0

Past Performance



NAV Information



TOP 10 holdings

Security	ISIN	Currency	Weight
TREASURY BILL 0% 26/12/2024	US912796ZV40	USD	9.089%
TREASURY BILL 0% 16/01/2025	US912797LY18	USD	7.502%
TREASURY BILL 0% 09/01/2025	US912797LX35	USD	7.479%
TREASURY BILL 0% 02/01/2025	US912797LR66	USD	7.433%
TREASURY BILL 0% 03/12/2024	US912797ME45	USD	7.094%
TREASURY BILL 0% 10/12/2024	US912797MN44	USD	7.080%
TREASURY BILL 0% 17/12/2024	US912797MP91	USD	7.065%
TREASURY BILL 0% 12/12/2024	US912797LP01	USD	6.989%
TREASURY BILL 0% 05/12/2024	US912797LF29	USD	6.957%
TREASURY BILL 0% 19/12/2024	US912797LQ83	USD	6.907%

Authorized participants

Goldenberg Hehmeyer LLP 25 Canada Square, Canary Wharf London E14 5LB Tel: +44 (0) 207 390 33 35

Jane Street 10 Chiswell Street London EC1Y4UQ Tel: +44 (0) 203 100 34 00

FinEx Capital Management LLP 25 Green Street, London W1K 7AX Tel: +44 (0) 20 7663 3300 Email: info@finxcapital.com

Barclays Capital Securities Limited

5 North Colonnade London E14 4BB Tel: +44 (0) 203 134 52 78 LLC C SAV Capital

Khoroshevskove highway, Moscow, 125284, Russia room 12/1, 32A, Tel: +7 495 568-12-19 Email: a.popovina@sav.capital

Cifra broker LLC 18th floor, 1st Krasnogvardeysky proezd 15, Moscow, 123112, Russia Tel: +7 (495) 783-91-73 Email: info@cifra-broker.ru

Further information about FinEx Funds ICAV can be found in the prospectus and the supplement to the prospectus of the fund which is available at FinEx Group's website www.FinExETF.com

GENERAL DISCLAIMER

Investment in the products mentioned in this document may not be suitable for all investors. Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. The price of the investments may go up or down and the investor may not get back the amount invested. Your income is not fixed and may fluctuate. The value of investments involving exposure to foreign currencies can be affected by exchange rate movements. We remind you that the levels and bases of, and reliefs from, taxation can change. Finck has not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information, investment should be made on the basis of the relevant Prospectus which is available from your Broker, Financial Adviser or FinEx Investment Management LLP. We recommend you seek independent professional advice prior to investing. In respect of the products mentioned this document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from FinEx Investment Management LLP.

FinEx Investment Management LLP, which is authorised and regulated by the Financial Conduct Authority ('FCA'), having its registered office at 4, Hill Street, London, W1J 5NE, England, has issued this document. FinEx ETFs constitute exchange traded funds issued by an Irish domiciled company, FinEx Funds ICAV established under Irish law (the "Fund"). FinEx Funds ICAV (the "company") is an open-ended investment company with variable capital having segregated liability between their funds organised under the laws of Ireland and authorised by the Financial Regulator.

For professional investors in the UK: Please note that the Fund is not registered in the United Kingdom. Most of the protections provided by the UK regulatory system do not apply to the operation of the Company, and compensation will not be available under the UK Financial Services Compensation Scheme on its default. The Company is a recognised scheme for the purposes of the Financial Services and Markets Act 2000.

This document is not, and under no circumstances is to be construed as, an advertisement, or any other step in furtherance of a public offering of shares in the United States or Canada. This document is not aimed at persons who are resident in the United States, Canada or any province or territory thereof, where the Companies are not authorised or registered for distribution and where no prospectus for the Companies has been filed with any securities commission or regulatory authority. The Company may not be acquired or owned by, or acquired with the assets of, an ERISA Plan.

Barclays is a trademark of Barclays Bank PLC and is used by FinEx under licence. The Fund is not sponsored, endorsed, sold or promoted by Barclays and Barclays makes no representation regarding the advisability of investing in the Fund.